Expert opinion on emerging urate-lowering therapies.

Academic Article

Abstract

  • INTRODUCTION: There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate (levotofisopam, ulodesine, verinurad, merbarone, KUX-1151, UR-1102, FYU-981, SEL-212), or treating gout flares (canakinumab, bucillamine) or both (arhalofenate, diacerein). Expert opinion: Among therapies with both urate lowering and anti-inflammatory action, arhalofenate seems promising, but more data are needed. Examining therapies aimed at treating gout flares [anti-inflammatory action], bucillamine has some potential, but more data and Phase III studies are needed, to better understand its efficacy and safety. Among the urate-lowering therapies (ULTs), verinurad seems to be the most promising, while levotofisopam and ulodesine require more data. A uricase-replacement therapy with improved immune reaction (SLE-212) is in a Phase II trial. A number of ULTs including KUX-1151, UR-1102 and FYU-981 are in early development and more will be known once initial data and studies are published.
  • Published In

    Keywords

  • Emerging therapies, FYU-981, RLBN-1001, SEL-212, UR-1102, arhalofenate, bucillamine, diacerein, gout, hyperuricemia, levotofisopam, merbarone, ulodesine, urate lowering therapy, verinurad, Anti-Inflammatory Agents, Drug Design, Gout, Gout Suppressants, Humans, Hyperuricemia, Uric Acid
  • Digital Object Identifier (doi)

    Authorlist

  • Stamp LK; Merriman TR; Singh JA
  • Start Page

  • 201
  • End Page

  • 209
  • Volume

  • 23
  • Issue

  • 3